###begin article-title 0
###xml 2 3 2 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 87 90 87 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 95 98 95 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
EC5S Ubiquitin Complex Is Recruited by KSHV Latent Antigen LANA for Degradation of the VHL and p53 Tumor Suppressors
###end article-title 0
###begin p 1
###xml 288 289 288 289 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 359 364 359 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(VHL)</italic>
###xml 369 372 369 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 721 724 721 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 729 732 729 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 915 918 915 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 923 926 923 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1003 1006 1003 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 1011 1014 1011 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
Cellular protein degradation pathways can be utilized by viruses to establish an environment that favors their propagation. Here we report that the Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded latency-associated nuclear antigen (LANA) directly functions as a component of the EC5S ubiquitin complex targeting the tumor suppressors von Hippel-Lindau (VHL) and p53 for degradation. We have characterized a suppressor of cytokine signaling box-like motif within LANA composed of an Elongin B and C box and a Cullin box, which is spatially located at its amino and carboxyl termini. This motif is necessary for LANA interaction with the Cul5-Elongin BC complex, to promote polyubiquitylation of cellular substrates VHL and p53 in vitro via its amino- and carboxyl-terminal binding domain, respectively. In transfected cells as well as KSHV-infected B lymphoma cells, LANA expression stimulates degradation of VHL and p53. Additionally, specific RNA interference-mediated LANA knockdown stabilized VHL and p53 in primary effusion lymphoma cells. Thus, manipulation of tumor suppressors by LANA potentially provides a favorable environment for progression of KSHV-infected tumor cells.
###end p 1
###begin title 2
Synopsis
###end title 2
###begin p 3
###xml 1029 1034 1025 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(VHL)</italic>
###xml 1039 1042 1035 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1269 1272 1265 1268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 1277 1280 1273 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1473 1478 <span type="species:ncbi:9606">human</span>
Ubiquitin is a small 8.5-kDa polypeptide with 76 amino acids which is highly conserved in eukaryotes. Cellular proteins destined for degradation are covalently linked to ubiquitin by a process called ubiquitylation. This highly regulated process controls a broad range of fundamental cellular functions, including signal transduction, development, and apoptosis. Many pathogens invade host cells by mimicking, blocking, or redirecting the activity of the cellular ubiquitin system. Understanding the unique biological functions targeted by these pathogens is a key goal in developing strategies for prevention and protection against their invasions. This report describes a unique functional role of the latency-associated nuclear antigen (LANA) encoded by Kaposi's sarcoma-associated herpesvirus, a large DNA virus that persists in primary effusion lymphoma and multicentric Castleman's disease. LANA can modulate hypoxia-inducible factor 1alpha activities by down-regulation of the critical tumor suppressors von Hippel-Lindau (VHL) and p53 in B lymphoma cells. In this pathway, LANA directly mimics and serves as an adaptor molecule for a specific E3 ubiquitin complex through an unconventional protein motif, to stimulate the ubiquitylation and degradation of both VHL and p53. This is of fundamental importance because it raises the interesting question as to whether this process is linked to regulation of infection and pathogenesis by tumor viruses associated with human cancers.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 221 222 221 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b001">1</xref>
###xml 370 371 370 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b002">2</xref>
###xml 372 373 372 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b003">3</xref>
###xml 486 487 486 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b004">4</xref>
###xml 749 750 749 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b005">5</xref>
###xml 751 752 751 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b008">8</xref>
###xml 828 829 828 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b009">9</xref>
###xml 830 832 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b010">10</xref>
###xml 965 967 965 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b011">11</xref>
###xml 968 970 968 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b015">15</xref>
###xml 1099 1102 1096 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1259 1261 1253 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b016">16</xref>
###xml 1262 1264 1256 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b019">19</xref>
###xml 458 466 <span type="species:ncbi:9606">patients</span>
###xml 476 484 <span type="species:ncbi:9606">patients</span>
Kaposi's sarcoma-associated herpesvirus (KSHV) is a DNA tumor virus of the rhadinovirus subfamily associated with rare endothelial and lymphoid cancers which was first discovered in Kaposi's sarcoma (KS) lesions in 1994 [1]. It is also tightly linked to other lymphoproliferative disorders including primary effusion lymphoma (PEL) and multicentric Castleman's disease [2,3]. The rate of KS disease is increased by immunosuppression in both organ transplant patients and AIDS patients [4]. The KSHV-encoded latency-associated nuclear antigen (LANA) is initially identified as a DNA binding, nuclear transcription factor that also contributes to KSHV latent replication by maintaining the viral episome and is also involved in regulation of latency [5-8]. LANA targets downstream viral promoters through both direct DNA binding [9,10] and formation of protein complexes with at least four other cellular DNA binding transcription factors: CREB, CBP, Sp1, and STAT3 [11-15]. LANA also interacts physically with a number of cellular proteins, such as p53, pRB, and GSK3beta, resulting in inhibition of p53-mediated apoptosis, chromosome instability, derepression of Rb-transcriptional activities, and dysregulation of beta-catenin and the Wnt signaling pathway [16-19].
###end p 5
###begin p 6
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b020">20</xref>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b022">22</xref>
###xml 263 266 263 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b023">23</xref>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b024">24</xref>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b025">25</xref>
###xml 694 696 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b022">22</xref>
###xml 1152 1154 1152 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b021">21</xref>
###xml 1155 1157 1155 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b026">26</xref>
###xml 1158 1160 1158 1160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b027">27</xref>
###xml 1303 1305 1303 1305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b021">21</xref>
###xml 1568 1570 1565 1567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b028">28</xref>
###xml 1753 1755 1750 1752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b029">29</xref>
###xml 1756 1758 1753 1755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b030">30</xref>
###xml 1913 1915 1910 1912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b031">31</xref>
###xml 1916 1918 1913 1915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b034">34</xref>
###xml 2012 2014 2009 2011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b035">35</xref>
###xml 2015 2017 2012 2014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b036">36</xref>
###xml 2155 2157 2152 2154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b037">37</xref>
###xml 2158 2160 2155 2157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b040">40</xref>
###xml 272 275 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Protein ubiquitylation is important for regulation of a range of cellular processes in eukaryotes, including signal transduction, development, apoptosis, cell cycle progression, endocytosis, and immune response [20-22]. Many pathogens such as HPV (E6 deregulates p53) and HIV (Vif targets APOBEC3G) [23,24] have evolved numerous strategies to control protein degradation by mimicking, blocking, or redirecting the activity of the ubiquitin system [25]. In the ubiquitin proteolytic pathways, there are two distinct steps as follows: the covalent attachment of multiple ubiquitin molecules to the protein substrate and the degradation of the ubiquitylated protein by the 26S proteasome complex [22]. The system responsible for ubiquitin attachment consists of several components that act in concert. Using ATP as a substrate, a ubiquitin-activating enzyme E1 (i.e., Uba1) catalyzes the formation of a thioester bond between itself and ubiquitin and then transfers the activated ubiquitin to a ubiquitin-conjugating enzyme E2 (i.e., Ubc5a), which together with a ubiquitin-protein ligase E3 or not specifically transfers ubiquitin to the target protein [21,26,27]. The E3 ligase is generally thought to be a group of multisubunit complexes which are mostly responsible for substrate specific recognition [21]. To date, this group consists of a superfamily of E3 ligase complex including the following: (1) SCF (Skp1-Cul1-F-box)-in this complex, Skp1 links the scaffold protein Cullin (Cul)1 to the substrate-specific adapter referred to as an F-box protein (beta-TrCP) [28]; (2) ECS (Elongin C-Cul2/5-SOCS [suppressors of cytokine signaling]-box) complex, in which Elongin C bridges Cul2 or Cul5 to the SOCS-box-containing adaptor protein (SOCS and VHL) [29,30]; (3) BC3B (BTB-Cul3-BTB), in which the Skp1 and Elongin C structurally homologous protein BTB interacts with Cul3 to degrade target substrates (MEL-26) [31-34]; and (4) APC/C (APC2-C) E3 ligase complex, which probably using Cul4 protein as a scaffold [35,36]. Interestingly, in KSHV, the viral K3 and K5 proteins identified as PHD domain-containing E3 ubiquitin ligases enrich this superfamily [37-40].
###end p 6
###begin p 7
###xml 263 265 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b041">41</xref>
###xml 266 268 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b043">43</xref>
###xml 389 394 377 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(VHL)</italic>
###xml 419 420 407 408 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 443 445 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b029">29</xref>
###xml 451 454 439 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 492 494 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b044">44</xref>
###xml 705 708 689 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 713 716 697 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 718 720 702 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b029">29</xref>
###xml 721 723 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b044">44</xref>
Hypoxia-inducible factor 1alpha (HIF-1alpha) is a subunit of the heterodimer HIF-1 transcription factor that specifically responds to hypoxia and activates a set of genes known to be involved in angiogenesis, cell proliferation, survival, and glucose metabolism [41-43]. In normoxia, HIF-1alpha is targeted for ubiquitylation and degradation by both the tumor suppressor von Hippel-Lindau (VHL) as a component of the EC2S E3 ubiquitin ligase [29] and p53-associated Mdm2 as an SCF E3 ligase [44]. Previous studies have shown that the transcriptional activity of HIF-1alpha is increased not only by intratumoral hypoxia but also by genetic alterations and loss of function of cellular regulators including VHL and p53 [29,44].
###end p 7
###begin p 8
###xml 113 116 109 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 121 124 117 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 234 238 230 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL-</italic>
###xml 243 246 239 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 333 336 325 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 341 344 333 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 553 556 545 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 561 564 553 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
In this report, we investigated the mechanisms by which the KSHV encoded LANA targets the HIF-1alpha suppressors VHL and p53 for degradation. LANA recruits the ubiquitin-proteasome pathway resulting in a powerful inhibitory effect on VHL- and p53-mediated HIF-1alpha degradation. The mechanism that involves binding to and targeting VHL and p53 for degradation is mediated by an unconventional intrinsic ubiquitin E3 ligase activity encoded by the SOCS-box-like motif of LANA. These results imply that this ubiquitin-proteasome pathway regulates normal VHL and p53 turnover and show that their destabilizations are greatly enhanced by interaction with LANA. This can contribute to a disruption of the induced antiviral state during the KSHV latent infection.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
Identification of LANA as an Elongin BC Interacting Protein
###end title 10
###begin p 11
###xml 641 643 641 643 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 816 817 816 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
###xml 902 910 902 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g001">Figure 1</xref>
###xml 1178 1186 1178 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g001">Figure 1</xref>
###xml 1447 1455 1447 1455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g001">Figure 1</xref>
###xml 81 86 <span type="species:ncbi:4932">yeast</span>
###xml 173 178 <span type="species:ncbi:9606">human</span>
###xml 450 455 <span type="species:ncbi:4932">yeast</span>
###xml 533 538 <span type="species:ncbi:4932">yeast</span>
Previously, to identify binding partners for KSHV-encoded latent protein LANA, a yeast two-hybrid screen was performed using LANA as bait, together with a cDNA library from human endothelial cells. One cDNA identified in this screen was found to encode Elongin C. Since Elongin C has been shown to directly bind to BC-box containing proteins which usually interact with Elongin B and C complex (Elongin BC), the association of LANA with Elongin C in yeast is likely to also involve Elongin B. To confirm the binding results from the yeast two-hybrid screen, we examined in vitro binding assays of Elongin BC to LANA. In in vitro translated [35S]-labeled methionine, different truncated forms (N: 1-340 amino acids [aa], C: 762-1162 aa, and NC: 1-327̂929-1162 aa) of LANA with myc tag were incubated with glutathione S-transferase (GST)-fused Elongin B (Elo. B) or Elongin C (Elo. C) beads. As shown in Figure 1A, LANA did not bind Elongin B, whereas it clearly bound to Elongin C. Moreover, the amino-terminal domain of LANA predominantly interacted with Elongin C. This was further confirmed by reverse immunoprecipitation (IP) using a myc-tagged LANA N truncated polypeptide (Figure 1B, lanes 5 and 6). In further experiments, association between LANA and the Elongin BC complex was assessed in co-IP experiments. Interestingly, Elongin B efficiently precipitated with the amino-terminal domain of LANA only when incubated along with Elongin C (Figure 1B, compare lanes 6 and 7).
###end p 11
###begin p 12
###xml 434 442 434 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g001">Figure 1</xref>
To specifically address the question as to whether or not LANA does associate with the Elongin BC complex in KSHV-infected cells, co-IP assays were done in PEL cells positive for KSHV as well as an isogenic set of BJAB cell lines with and without KSHV infection. The results of this assay nicely showed that LANA associates with Elongin B as well as Elongin C in the PEL cell line BCBL-1 as well as in a KSHV-infected BJAB cell line (Figure 1C). This suggests that LANA does exist in complex with Elongin BC in KSHV-positive cells.
###end p 12
###begin title 13
The LANA/Elongin BC Complex Interacted with a Cul5/Rbx1 Module
###end title 13
###begin p 14
###xml 477 485 477 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g002">Figure 2</xref>
###xml 616 624 616 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g002">Figure 2</xref>
###xml 853 861 853 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g002">Figure 2</xref>
###xml 964 972 964 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g002">Figure 2</xref>
The Elongin BC complex was shown to be involved in ubiquitylation as a component of the ECS E3 complex. To determine whether the Elongin BC complex could function as an adaptor which links LANA to a Cullin/Rbx1 module, thus reconstituting an E3 ubiquitin ligase complex, IP assays against myc tag were performed on lysates of Saos-2 cells cotransfected with hemagglutinin (HA)-Rbx1 and HA-Cullin (Cul2 or Cul5) in the presence or absence of myc-tagged LANA expression vectors (Figure 2A). The results showed that LANA did not associate with the Cul2/Rbx1module. However, LANA did assemble with the Cul5/Rbx1 module (Figure 2A). Further experiments with or without Elongin BC coexpression demonstrated that LANA-Elongin BC complex did assemble with the Cul5/Rbx1 module to reconstitute a multiprotein complex containing LANA, Elongin BC, Rbx1, and Cul5 (Figure 2B) and the Elongin BC complex can increase the affinity of LANA interaction with Cul5 and Rbx1 module (Figure 2B).
###end p 14
###begin title 15
The SOCS-Box-Like Motif Is Essential for LANA Association with Cul5-Elongin BC Complex
###end title 15
###begin p 16
###xml 66 69 66 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b030">30</xref>
###xml 261 262 261 262 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 266 267 266 267 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 363 365 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b030">30</xref>
###xml 665 668 663 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 1183 1186 1181 1184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 1617 1625 1615 1623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g003">Figure 3</xref>
###xml 1496 1509 <span type="species:ncbi:9544">rhesus monkey</span>
###xml 1524 1527 <span type="species:ncbi:11029?0.43884892086330934|species:ncbi:154334?0.05755395683453238">RRV</span>
###xml 1532 1551 <span type="species:ncbi:10381">herpesvirus saimiri</span>
A well-known family of Elongin BC-interacting proteins, including VHL tumor suppressor and SOCS proteins, has been recently identified as SOCS-box proteins [30]. These proteins directly interact with Elongin BC through their conserved BC-box motif [(A/P/S/T)L-x3-C-x3-(A/I/L/V)] and associate with Cullin proteins through the conserved Cul-box motif [PhixxLPxP] [30]. Moreover, the two Cul boxes, the Cul2 box and the Cul5 box, are specific for distinguishing binding with the different Cullin proteins (Cul2 or Cul5). To determine whether LANA interacts with Elongin BC and the Cullin protein through its SOCS-box motif, we first aligned the sequence of LANA with VHL and SOCS (1, 2, and 3) proteins. Our analysis showed that LANA probably also contains an SOCS-box-like motif based on the hydrophobic homology of consensus sequences. However, the BC box and Cul box in this viral SOCS-box motif are atypical as distinguished from the BC box which is usually close to the Cul box found in SOCS-box motifs of cellular proteins. In KSHV LANA these motifs were separately located from each other in the amino-terminal and the carboxyl-terminal domains. Furthermore, in contrast to the VHL Cul2 box and SOCS protein Cul5 box, the LANA Cul box was significantly similar to the Cul box of the SOCS protein family. This supports the evidence of LANA associated with Cul5, not Cul2, protein in the IP assay above. Additionally, the ORF73 homolog of LANA encoded by other gammaherpesvirus, including the rhesus monkey rhadinovirus (RRV) or herpesvirus saimiri (HVS A11 and C488), also contains a similar SOCS-box-like motif (Figure 3A).
###end p 16
###begin p 17
###xml 364 372 364 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g003">Figure 3</xref>
###xml 577 585 577 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g003">Figure 3</xref>
###xml 709 717 709 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g003">Figure 3</xref>
###xml 772 774 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b024">24</xref>
###xml 775 777 775 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b030">30</xref>
###xml 778 780 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b045">45</xref>
###xml 781 783 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b047">47</xref>
###xml 1080 1088 1080 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g003">Figure 3</xref>
To confirm that LANA associates with Elongin BC and Cullin 5 protein through its BC-box and Cul box motif, the corresponding site-specific mutation and deletion of the LANA SOCS-box-like motifs were generated. Co-IP assays using different LANA mutants showed that the BC-box motif deletion mutant resulted in a failure of LANA to bind with the Elongin BC complex (Figure 3B). Additionally, LANA mutants with specific site mutations in the BC-box motif also resulted in a decrease in the ability of LANA to bind to the Elongin BC complex when compared with wild-type (WT) LANA (Figure 3B). LANA binding with Cul5/Rbx1 module and Elongin BC complex was completely disrupted when the SOCS-box motif was deleted (Figure 3C). Cul5 is known to interact with Elongin BC complex [24,30,45-47]. Thus, when the LANA Cul-box motif deletion mutant was coexpressed with Elongin BC and tested for binding to the Cul5/Rbx1 module and Elongin BC complex, we observed that the LANA mutants with Cul5 box deletion had same remaining binding activity to the Cul5/Rbx1 module and Elongin BC complex (Figure 3C). To confirm Cul-box motif is necessary for LANA to specifically bind Cul5 protein, further experiments were performed and demonstrated that LANA with the Cul-box deleted lost binding to the Cul5 protein when assayed without the Elongin BC complex coexpression (unpublished data). Taken together, these data suggest that these motifs are critical for LANA interaction with the Elongin BC/Cul5/Rbx1 module and indicate that BC-box motif and Cul-box motif are likely to be in close proximity in terms of the spatial structure of the LANA protein in order to constitute an intact SOCS-box motif.
###end p 17
###begin title 18
The LANA-Elongin BC Complex Is Capable of Assembling with Cul5/Rbx1 Module to Reconstitute an E3 Ubiquitin Ligase
###end title 18
###begin p 19
###xml 353 361 353 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g003">Figure 3</xref>
###xml 529 537 529 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g003">Figure 3</xref>
###xml 725 733 725 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g003">Figure 3</xref>
###xml 935 943 931 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g003">Figure 3</xref>
To investigate whether the LANA-Elongin BC-Cul5-Rbx1 complex possesses ubiquitin ligase activity, the complex was immunoaffinity purified and assayed for its ability to activate formation of polyubiquitin chains by the E2 ubiquitin-conjugating enzyme Ubc5a in the presence of ATP, the E1 ubiquitin-activating enzyme Uba1, and GST-ubiquitin. As shown in Figure 3D, the LANA-Elongin BC-Cul5-Rbx1 complex stimulated formation of a ladder suggesting polyubiquitylation of the GST-ubiquitin, whereas the LANA SOCS-box mutant did not (Figure 3D, left panel, lanes 6 and 7). As expected, formation of polyubiquitin conjugates depended on the presence of the E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme, and ATP (Figure 3D). In addition, in vivo proteasome inhibitor assays further showed that WT LANA was capable of significantly enhancing polyubiquitylation activities when compared to that of the LANA DeltaSOCS mutant (Figure 3D, right panel, lanes 2 and 3).
###end p 19
###begin title 20
Elongin BC Binding Increases Stability of LANA Expressed in Cells
###end title 20
###begin p 21
###xml 782 790 778 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g004">Figure 4</xref>
###xml 1054 1062 1050 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g004">Figure 4</xref>
During our studies, we observed that the levels of WT LANA coexpressed with Elongin BC were consistently increased. Therefore, to determine whether this increase in levels of WT LANA could be attributed at least in part to potential stabilization of LANA by Elongin BC, WT LANA or the SOCS-box-like motif deletion mutant (DeltaSOCS) was transiently expressed in Saos-2 cells with or without Elongin BC. Twenty-four hours after transfection, cyclohexamide was added to cultures to block further protein synthesis, and the rate of decay of WT and mutant LANA protein was measured by Western blot analysis. The results showed that the level of WT LANA protein remained constant for at least 24 h after treatment of cyclohexamide to cells cotransfected with LANA along with Elongin BC (Figure 4A, left panel, and 4B). However, in the absence of cotransfected Elongin BC when an SOCS-box deletion mutant of LANA was used, almost 50% of the LANA protein was lost within 5 h. Thus, WT LANA protein exhibits increased stability when coexpressed with Elongin BC (Figure 4A, right panel, and 4B). In contrast to WT LANA, the DeltaSOCS LANA mutant exhibited similar instability in the presence or absence of cotransfected Elongin BC (unpublished data), suggesting a requirement for the SOCS-box-like motif of LANA for enhanced stability.
###end p 21
###begin title 22
###xml 32 35 32 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 40 43 40 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
Levels of the Tumor Suppressors p53 and VHL Are Significantly Reduced in LANA-Expressing Cells
###end title 22
###begin p 23
###xml 143 146 143 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 151 154 151 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b017">17</xref>
###xml 533 541 533 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g005">Figure 5</xref>
###xml 653 661 649 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g005">Figure 5</xref>
###xml 997 1005 993 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g005">Figure 5</xref>
###xml 1048 1051 1044 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1056 1059 1052 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 1187 1190 1183 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1195 1198 1191 1194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 1280 1288 1276 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g005">Figure 5</xref>
###xml 1331 1334 1327 1330 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1339 1342 1335 1338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 1554 1557 1550 1553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1562 1565 1558 1561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 1621 1629 1617 1625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g005">Figure 5</xref>
###xml 1693 1696 1689 1692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1701 1704 1697 1700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 1849 1857 1845 1853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g005">Figure 5</xref>
To determine the effect of LANA on targeted protein degradation, we examined the endogenous levels of some cellular tumor suppressors (such as p53 and VHL) expression in KSHV-positive (BCBL-1, JSC-1, BC-3, and BC-1) and -negative (BJAB, Louckes, and DG75) cell lines. Similar to previous studies which showed that p53 protein expression was decreased in KSHV-positive cells [17], our Western blot analysis of four KSHV-positive PEL cell lines showed that p53 levels were significantly reduced compared to KSHV-negative B cell lines (Figure 5A). Additionally, the levels of the HIF-1alpha-suppressor protein VHL were also reduced in KSHV-positive cells (Figure 5A). To avoid the inconsistency of genotype among different cell lines, we also compared the levels of p53 and VHL in cell lines with the same genotypic background BJAB and KSHV-infected BJAB. The resulting data further confirmed that levels of the tumor suppressor proteins p53 and VHL did dramatically reduce after the KSHV infection (Figure 5B). To determine that the results for both p53 and VHL inhibition was associated with LANA, stable 293 cell lines expressing LANA were generated. Similar results of tumor suppressor p53 and VHL inhibition by LANA were observed when immunoblotting (IB) assays were performed (Figure 5C). To further confirm the role of LANA on p53 and VHL inhibition, LANA in the KSHV-positive BCBL-1 cell line was knocked down by the introduction of small interference RNA specifically against LANA. Again, analysis using IB assays showed that the tumor suppressors p53 and VHL were greatly rescued on inhibition of LANA expression (Figure 5D, left panel). Furthermore, no obvious change was observed for p53 and VHL mRNA transcripts after LANA transcripts were decreased, supporting the hypothesis that LANA can induce the degradation of p53 and VHL proteins (Figure 5D, right panel).
###end p 23
###begin title 24
###xml 33 36 33 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 41 44 41 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
LANA Mediates the Degradation of p53 and VHL through Ubiquitylation
###end title 24
###begin p 25
###xml 108 111 108 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 116 119 116 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 161 162 161 162 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 196 199 196 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b017">17</xref>
###xml 322 325 322 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 341 343 341 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 516 519 516 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 588 591 588 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 659 667 659 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g006">Figure 6</xref>
###xml 782 785 782 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 790 793 790 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 795 803 795 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g006">Figure 6</xref>
We wanted to explore whether the potential mechanism for LANA-mediated degradation of the tumor suppressors p53 and VHL was related to LANA recruitment of the EC5S ubiquitin E3 ligase complex. As p53 was shown to interact with the carboxyl-terminal domain of LANA [17], we first determined the binding domain of LANA with VHL with in vitro [35S]-labeled methionine translated proteins using the p53 protein as a positive control. The results of the in vitro pulldown assays showed that distinct from LANA binding to p53 through its carboxyl-terminal domain, the region of LANA binding to VHL was located in the amino-terminal domain using in vitro IP assays (Figure 6A). Supporting in vivo IP assays further confirmed that full-length LANA was associated with the tumor suppressors p53 and VHL (Figure 6B).
###end p 25
###begin p 26
###xml 72 73 72 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 104 107 104 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 112 116 112 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL,</italic>
###xml 201 202 201 202 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 239 242 239 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 392 395 392 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 515 523 511 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g007">Figure 7</xref>
###xml 589 592 585 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 670 673 662 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 701 709 693 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g007">Figure 7</xref>
###xml 810 813 802 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 831 839 823 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g007">Figure 7</xref>
###xml 905 908 897 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 926 934 918 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g007">Figure 7</xref>
###xml 1059 1062 1051 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1067 1070 1059 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 1159 1162 1151 1154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1167 1170 1159 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 1401 1403 1393 1395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b029">29</xref>
###xml 1404 1406 1396 1398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b044">44</xref>
To determine the extent of the involvement of LANA recruitment of the EC5S E3 ligase for degradation of p53 and VHL, we utilized the specific SOCS-box mutant of LANA which lacks association with the EC5S complex. The constructs expressing p53, HA-ubiquitin (Ub), and WT LANA or its SOCS-deleted mutant were cotransfected into Saos-2 cells. The Western blot data showed that ubiquitylation of p53 in the presence of LANA was dramatically increased but minimally so when the DeltaSOCS mutant of LANA was coexpressed (Figure 7A, left panel, lanes 4 and 6). Similarly, WT LANA also can induce VHL polyubiquitylation more efficiently when compared to the DeltaSOCS mutant in VHL-deficient cell line 786-O (Figure 7A, right panel, lanes 10 and 12). Unexpectedly, the level of LANA could be seen to be decreased when p53 was coexpressed (Figure 7A, compare lane 5 with lanes 3 and 4) and slightly decreased when VHL was coexpressed (Figure 7A, compare lane 11 with lanes 10 and 12). This indicated that although LANA can mediate degradation of the tumor suppressors p53 and VHL through interaction with its amino and carboxyl-terminal domains, the tumor suppressors p53 and VHL are also likely to contribute to regulation of LANA levels, as both are components of two separate E3 ligase complex that may also regulate LANA's activity, and these activities may functionally compete in virally infected cells [29,44].
###end p 26
###begin p 27
###xml 48 51 48 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 56 59 56 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 172 175 172 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 183 186 183 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 298 301 298 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 309 312 309 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 407 415 407 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g007">Figure 7</xref>
To detect the specificity of LANA for targeting p53 and VHL for degradation, in vitro, LANA-Elongin BC-Cul5 complex ubiquitylation assays were performed using purified GST-p53 or GST-VHL as substrates. The results showed that only WT LANA could specifically recruit ubiquitin complex to induce GST-p53 or GST-VHL polyubiquitylation, but not its SOCS-deleted mutant or vector control in this in vitro assay (Figure 7B).
###end p 27
###begin title 28
###xml 35 38 35 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 42 45 42 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
Aberrantly Expressed LANA Conquers p53 or VHL Function as Components of E3 Ubiquitin Complexes Leading to Their Degradation
###end title 28
###begin p 29
###xml 8 11 8 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 16 19 16 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 144 147 144 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 152 155 152 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 307 310 307 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 314 317 314 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 441 443 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b029">29</xref>
###xml 444 446 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b044">44</xref>
###xml 503 506 499 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 510 513 506 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 565 568 561 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 573 576 569 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 605 614 601 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0020116-sg001">Figure S1</xref>
###xml 620 622 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0020116-sg001">S1</xref>
###xml 658 661 654 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 737 741 729 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53,</italic>
###xml 842 845 830 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 868 877 852 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0020116-sg001">Figure S1</xref>
###xml 934 937 918 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 995 1004 979 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0020116-sg001">Figure S1</xref>
###xml 1129 1132 1109 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1137 1140 1117 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 1356 1359 1328 1331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1364 1367 1336 1339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 1548 1551 1512 1515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1556 1559 1520 1523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 1561 1570 1525 1534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0020116-sg002">Figure S2</xref>
###xml 1696 1699 1660 1663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1704 1707 1668 1671 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
As both p53 and VHL are components of two separate E3 ubiquitin complexes, we wanted to determine whether aberrantly expressed LANA can conquer p53 and VHL functions as components of E3 ubiquitin complex leading to their degradation in KSHV-infected cells. We tested the interaction of the tumor suppressor p53 or VHL with LANA at different expression levels, as well as the effect on one of their downstream effectors proteins, HIF-1alpha [29,44]. As expression of LANA was increased without exogenous p53 or VHL coexpression, we found that LANA reduced levels of p53 and VHL in a dose-dependent manner (Figure S1A and S1B, right panels). As expected, when p53 was coexpressed with LANA and HIF-1alpha with increasing concentrations of p53, the levels of LANA as well as of HIF-1alpha levels were reduced, which was similar to expression of p53 and HIF-1alpha alone (Figure S1A, left panels). Similarly, increasing concentrations of VHL also inhibit LANA expression in a dose-dependent manner (Figure S1B, left panels). To determine the functional consequences of LANA on HIF-1alpha transcriptional activities in the context of p53 and VHL, reporter assays were performed using an HIF-1alpha response element reporter in various cell lines. The reporter assays further confirmed that the transcriptional activity of HIF-1alpha was strikingly reduced when p53 and VHL were cotransfected, whereas increased levels of LANA coexpressed rescued HIF-1alpha transcriptional activity most likely through targeting and degrading the HIF-1alpha suppressors p53 and VHL (Figure S2). Therefore, these results suggested that LANA expression is involved in regulating the degradation of the tumor suppressors p53 and VHL during KSHV-mediated oncogenesis, thus inhibiting their suppressive effects on HIF-1alpha transcriptional activities.
###end p 29
###begin title 30
Discussion
###end title 30
###begin p 31
###xml 333 334 333 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b006">6</xref>
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b048">48</xref>
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b051">51</xref>
###xml 1229 1231 1229 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b052">52</xref>
###xml 1232 1234 1232 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b053">53</xref>
###xml 1380 1381 1380 1381 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 3 9 <span type="species:ncbi:9606">humans</span>
In humans, targeting regulators of angiogenesis to proteasome-mediated degradation in virus-infected cells is getting increasing attention. The KSHV-encoded latent protein LANA was originally identified as a major viral antigen whose expression plays a crucial role in replication and maintenance of the viral episomes in PEL cells [6,48-51]. Here we demonstrated that the KSHV-encoded LANA protein interacts with the Elongin BC complex through the binding of Elongin C to the LANA BC-box motif located within its amino terminus. The LANA-Elongin BC complex was capable of assembling with a Cullin/Rbx1 module to reconstitute a multiprotein complex with ubiquitin ligase activity. Furthermore, the facts that LANA only associated with Cul5, and not with Cul2, and that a mutation in the Cul-box motif of LANA at its carboxyl terminus abolished Cul5 binding in the absence of Elongin BC indicate that LANA can directly interact with Cul5. Interaction of the Elongin BC complex with the BC box markedly increased the stability of LANA protein, suggesting that it may be necessary to protect LANA from degradation in order to assemble the functional E3 ubiquitin ligase complex, as previously proposed for SOCS-box family proteins [52,53]. Thus, our results suggest that LANA can recruit the Elongin BC complex and Cul5/Rbx module through its SOCS-box-like motif to function as an EC5S ubiquitin ligase. Binding of the Elongin BC complex served to stabilize LANA, and binding to Cul5 provided a bridge to recruit Rbx1 and activate the ubiquitin-conjugating process.
###end p 31
###begin p 32
###xml 547 549 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b043">43</xref>
###xml 550 552 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b054">54</xref>
###xml 553 555 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b056">56</xref>
###xml 568 571 564 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 576 579 572 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 690 692 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b029">29</xref>
###xml 693 695 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b044">44</xref>
###xml 999 1001 987 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b017">17</xref>
###xml 1076 1079 1064 1067 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 1084 1087 1072 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1246 1247 1230 1231 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 1505 1507 1485 1487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b057">57</xref>
###xml 192 197 <span type="species:ncbi:9606">human</span>
###xml 532 537 <span type="species:ncbi:9606">human</span>
###xml 1462 1470 <span type="species:ncbi:9606">patients</span>
Ubiquitin conjugation to protein substrates is strictly regulated by the specificity of the ubiquitin-protein E3 ligase complex. Therefore, identification of key regulators of angiogenesis in human cancers targeted for proteasomal degradation and mediated by KSHV-encoded LANA is highly significant. Previous evidence has shown that HIF-1alpha is a critical regulator of numerous cellular growth factors and can also function as a regulator of tumor angiogenesis, growth, and metastasis and is commonly overexpressed in a number of human cancers [43,54-56]. Recently, VHL and p53 have been demonstrated to be involved in the regulation of HIF-1alpha through ubiquitin-mediated degradation [29,44]. In this study, we present data to show that the levels of the HIF-1alpha-suppressor protein VHL were dramatically decreased in KSHV-positive compared with KSHV-negative cells. Additionally, the tumor suppressor protein p53 was also significantly reduced in KSHV-infected cells as previously reported [17]. The WT LANA, but not mutant deleted for the SOCS-box motif, facilitated VHL and p53 ubiquitylation, suggesting that LANA is involved in the degradation of these HIF-1alpha-suppressor molecules and can function as an adaptor molecule to the EC5S ubiquitin ligase complex which contributes to the rescue of HIF-1alpha. These findings shed light on the unique property of KSHV latently infected KS lesions predominantly seen in the lower extremities in elderly patients in whom oxygen is typically poor [57].
###end p 32
###begin p 33
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b045">45</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b047">47</xref>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b058">58</xref>
###xml 780 782 780 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b059">59</xref>
###xml 812 814 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b046">46</xref>
###xml 792 795 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Interestingly, both Cul2 and Cul5 are known to be involved in ECS-type E3 ubiquitin ligase complex. As to why LANA preferentially associates with the Cul5 and not the Cul2 protein, our data suggest that the Cul-box motif as well as additional sequences in the vicinity located in the carboxyl terminus of LANA may be important in this selection process. The Cul5-Elongin BC complex was shown to interact with a number of SOCS-box-containing proteins, such as MUF1, ASB2, and the SOCS family of proteins [45,47,58]. Although the mechanism by which Cul5 functions in these processes remains unclear, some viral proteins recruiting Cul5-containing ECS ubiquitin ligase have been shown to regulate the turnover of molecules involved in cell-cycle control, such as adenovirus E4 orf6 [59] and the HIV vif-1 proteins [46]. Here the interaction of LANA with Cul5 further emphasizes a role for Cul5 in the regulation of virus-mediated dysregulation of cell growth and oncogenesis.
###end p 33
###begin p 34
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b030">30</xref>
###xml 521 524 521 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 529 532 529 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 657 665 657 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g008">Figure 8</xref>
A major difference between the SOCS-box motif of KSHV LANA and the consensus SOCS-box sequence of cellular proteins is the greater distance between the BC box and the Cul box in this motif [30]. Our data strongly suggest that this specific characteristic of the SOCS-box-like motif in ORF73 proteins encoded by other gammaherpesvirus is highly conserved and that this structure allows LANA greater flexibility for interaction with the Elongin C and Cullin proteins to achieve its function. The fact that LANA can bind to VHL and p53 via its amino- and carboxyl-terminal domains, respectively, inducing their degradation, is consistent with this hypothesis (Figure 8).
###end p 34
###begin p 35
###xml 64 67 64 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 72 75 72 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 231 232 227 228 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 306 309 302 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 335 339 331 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53-</italic>
###xml 445 448 441 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 453 456 449 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 458 460 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b029">29</xref>
###xml 461 463 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b044">44</xref>
###xml 776 785 772 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat-0020116-sg003">Figure S3</xref>
###xml 876 878 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b060">60</xref>
###xml 879 881 875 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b062">62</xref>
It is noteworthy to mention that the cellular tumor suppressors VHL and p53 can also inhibit the ability of the viral protein LANA to regulate HIF-1alpha levels when they are highly expressed, as they can also act as adaptors of EC2S- and SCF-type E3 ligase complex, respectively. Thus, the utilization of VHL-deficient 786-O cells or p53-deficient Saos-2 cells was critical for clearly defining the functional role of LANA in the regulation of VHL and p53 [29,44]. This also indicates that the balance between the cellular mechanisms usurped by KSHV and the host cellular defense mechanisms is critical for determination of cell fate. The higher levels of LANA expression in KSHV-infected cells are likely to be crucial to subdue the cellular defenses during KSHV infection (Figure S3), and this is consistent with the fact that LANA is highly expressed in KS and PEL cells [60-62].
###end p 35
###begin p 36
This study reinforces the view that regulation of protein degradation is an important mechanism for the control of angiogenesis and oncogenesis during KSHV latent infection.
###end p 36
###begin title 37
Materials and Methods
###end title 37
###begin title 38
Plasmids, cell lines, and culture.
###end title 38
###begin p 39
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b063">63</xref>
###xml 385 388 385 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 429 432 429 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b064">64</xref>
###xml 1505 1508 1501 1504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
Constructs expressing LANA full length and its truncated LANA1-340 (N), LANA762-1162 (C), and LANA1-327̂929-1162 (NC) in the pA3M vector were described previously [63]. Constructs expressing LANA with 212-222 aa (BC box), 1085-1091 aa (Cul box), or 212-222̂1085-1091 (SOCS box) aa deletion or site mutation (L213G, C217G, and L213PC217F) in pA3M were prepared by PCR mutagenesis. pA3M/p53 was constructed by Jason S. Knight. GST-p53 was as described previously [64]. Plasmids pCEP4/HIF-1alpha and pCEP4 were provided by Gregg L. Semenza (Johns Hopkins University School of Medicine, Baltimore, Maryland, United States). Plasmid pCMV/HA-VHL was provided by William G. Kaelin (Howard Hughes Medical Institute, Chevy Chase, Maryland, United States). Multimeric hypoxia response element (HRE) in pGL2-Basic vector was a gift from Craig B. Thompson (University of Pennsylvania Medical School, Philadelphia, Pennsylvania, United States). pcDNA3/HA-Rbx1 was provided by Yue Xiong (University of Rochester Lineberger Cancer Center, Rochester, New York, United States). pcDNA3/HA-Ub was provided by George Mosialos (Alexander Fleming Biomedical Sciences Research Center, Vari, Greece). VR1012/HA-Cul2 and VR1012/HA-Cul5 were provided by Xiao-Fang Yu (Johns Hopkins University School of Medicine). T7-Elongin B in pcDNA3.1, His-HPC4-Elongin C in pcDNA3.1, GST-ubiquitin in pGEX-4T-2, myc-Uba1-His in pET-23b, and His-hUbc5a-Flag in pRSETB were provided by Joan W. Conaway (University of Kansas Medical Center). GST-VHL (54-213) in pGEX-4T-3 was provided by Bill Kaelin (Howard Hughes Medical Institute). Constructs HA-Elongin B, HA-Elongin C, GST-Elongin B, and GST-Elongin C were obtained from Elongin B and Elongin C PCR products cloned into pcDNA-3HA and pGEX-2T vectors, respectively.
###end p 39
###begin p 40
###xml 16 19 16 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 144 147 144 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 479 480 478 479 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 789 791 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b065">65</xref>
###xml 125 130 <span type="species:ncbi:9606">Human</span>
###xml 211 216 <span type="species:ncbi:9606">Women</span>
###xml 632 638 <span type="species:ncbi:9913">bovine</span>
###xml 794 799 <span type="species:ncbi:9606">Human</span>
Renal carcinoma VHL-null cell line 786-O was kindly provided by Volker H. Haase (University of Pennsylvania Medical School). Human osteosarcoma p53-null cell line Saos-2 was obtained from Jon Aster (Brigham and Women's Hospital, Boston, Massachusetts, United States). BJAB, DG75 and Louckes KSHV-negative type cells and BC-3, BCBL-1, JSC-1 and BC-1 KSHV-positive type cells were maintained in RPMI 1640 medium (Invitrogen, Carlsbad, California, United States) with 7% FBS, 4 muM l-glutamine, penicillin, and streptomycin. The other cells were maintained in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 5% fetal bovine serum, penicillin, and streptomycin. BJAB cells latently infected with KSHV were kindly provided by Michael Lagunoff of the University of Washington [65]. Human embryonic kidney (HEK) 293/pA3M-LANA and 293/pA3M stable cell lines were selected by 1 mug/ml Puromycin. Cells were transfected by electroporation with a Bio-Rad (Hercules, California, United States) Gene Pulser in 0.4-cm cuvettes at 220 V and 975 muF.
###end p 40
###begin title 41
Antibodies, IB, and IP.
###end title 41
###begin p 42
###xml 191 194 191 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 387 390 383 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 26 31 <span type="species:ncbi:10090">mouse</span>
###xml 52 57 <span type="species:ncbi:10090">mouse</span>
###xml 287 292 <span type="species:ncbi:10090">Mouse</span>
###xml 376 381 <span type="species:ncbi:10090">mouse</span>
###xml 421 426 <span type="species:ncbi:10090">mouse</span>
###xml 472 477 <span type="species:ncbi:10090">mouse</span>
###xml 532 538 <span type="species:ncbi:9986">rabbit</span>
###xml 605 611 <span type="species:ncbi:9986">rabbit</span>
The monoclonal antibodies mouse anti-HA (12CA5) and mouse anti-myc (9E10) were purchased from Covance Research Products (Denver, Pennsylvania, United States). Anti-ubiquitin (FL-76) and anti-p53 (DO-1) were obtained from Santa Cruz Biotechnology (Santa Cruz, California, United States). Mouse anti-HIF-1alpha (BD Transduction Laboratory, San Jose, California, United States), mouse anti-VHL (BD Transduction Laboratory), mouse anti-Elongin B (BD Transduction Laboratory), mouse anti-Elongin C (BioLegend, San Diego, United States), rabbit anti-GST (Amersham Biosciences, Little Chalfont, United Kingdom), rabbit anti-LANA polyclonal antibody (provided by Bala Chandran of Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, United States), and anti-beta-actin (Cell Signaling Technology) were also used.
###end p 42
###begin p 43
###xml 484 485 481 482 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 487 488 484 485 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 497 498 494 495 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 501 502 498 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
Twenty million whole-cell lysates were extracted in 200 mul of radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris [pH 7.6], 150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 1 mug/ml aprotinin, and 1 mug/ml pepstatin). Protein concentration was determined by Bio-Rad protein assay. Protein was separated by SDS-PAGE and transferred onto polyvinylidene fluoride membranes. After blocking with 5% nonfat dry milk in PBS (2 mM KCl, 120 mM NaCl, 1.5 mM KH2PO4, 8 mM Na2HPO4) containing 0.1% Tween 20, proteins were probed with the corresponding antibodies. For detection of proteins, appropriate infrared-conjugated secondary antibodies (Alexa Fluor 800 or 680) were used with the Li-COR (Lincoln, Nebraska, United States) Odyssey scanner. For IP, after one-step preclearing (rotation 1 h, 4 degreesC) with protein A/G (50/50) Sepharose fast flow (Amersham Biosciences), antibodies were added to the cell protein extract in a binding buffer adjusted to 20 mM Tris (pH 7.5), 200 mM NaCl, and 0.1% Nonidet P-40. After overnight incubation, immunocomplexes were recovered with protein A/G (50/50) Sepharose for 1-h incubation. After three washes with binding buffer, proteins were eluted in sample buffer and resolved by SDS-PAGE electrophoresis.
###end p 43
###begin title 44
RNA interference.
###end title 44
###begin p 45
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b016">16</xref>
siRNAs complementary to the C-terminal (GCTAGGCCACAACACATCT) fragment of LANA as described previously [16] were cloned into the pSIREN vector according to the instruction of manufacture (Clontech, Palo Alto, California, United States) to generate si-LANA construct. pSIREN vector with luciferase target sequence was used as control. Ten million BCBL-1 cells were cotransfected by electroporation with 5 mug of si-LANA (or si-Luc). BCBL-1 knockdown stable cells were selected and maintained in 4 mug/ml puromycin.
###end p 45
###begin title 46
###xml 55 72 55 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli.</italic>
###xml 55 71 <span type="species:ncbi:562">Escherichia coli</span>
Expression and purification of recombinant proteins in Escherichia coli.
###end title 46
###begin p 47
###xml 38 45 38 45 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">E. coli</named-content>
###xml 638 640 626 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 929 930 917 918 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 38 50 <span type="species:ncbi:511693">E. coli BL21</span>
Overnight starter cultures (50 ml) of E. coli BL21 (DE3) transformed with pGEX-4T-GST-ubiquitin, pGEX-2T-Elongin B, pGEX-2T Elongin C, pET-23b-myc-Uba1-His, and pRSETB-His-hUbc5a-Flag were incubated into 500 ml of culture medium and grown at 30 degreesC to an optical density of about 0.6 at 600 nm. After IPTG induction (0.5 mM, 2 h at 30 degreesC), bacteria were collected and sonicated in lysis buffer containing 20 mM Tris-HCl (pH 8.0), 100 mM NaCl, 0.5% Nonidet P-40, 1 mM EDTA, 1 M DTT, 5% Sarkosyl, and the protease inhibitor cocktail for use with mammalian cell extracts. Uba1, Ubc5, and His-ubiquitin proteins were purified by Ni2+-NTA agarose chromatography (Qiagen, Valencia, California, United States), and GST-ubiquitin, GST-Elongin B, or GST-Elongin C was purified by glutathione sepharose chromatography (Amersham Biosciences) and then dialyzed against 40 mM HEPES-NaOH (pH 7.9), 60 mM potassium acetate, 1 mM MgCl2, 0.5 mM EDTA, 10% glycerol, and 2 mM DTT.
###end p 47
###begin title 48
Pulldown assays.
###end title 48
###begin p 49
###xml 60 69 60 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53, VHL,</italic>
###xml 124 126 124 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 507 508 497 498 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 777 778 761 762 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
T7 promoter fused cDNA for expressing Elongin B, Elongin C, p53, VHL, or LANA derivatives was incubated in the presence of [35S]methionine for 3 h at 30 degreesC according to the manufacturer's instructions (Promega, Madison, Wisconsin, United States). Translation products of 15 mul of each protein were incubated with 1 mul of anti-myc (9E10) antibody (for GST pulldown, incubated with GST, or GST-tagged recombinant protein) in 500 mul of binding buffer (50 mM Tris-HCl [pH 7.5], 100 mM NaCl, 10 muM ZnCl2, 10% glycerol, freshly supplemented with 0.1 mM DTT and protease inhibitor) overnight at 4 degreesC. Proteins were recovered with protein A/G (50/50) Sepharose for 1-h incubation. After three washes with washing buffer (50 mM Tris-HCl [pH 7.5], 100 mM NaCl, 10 mM MgCl2, 5% glycerol, 0.1% Nonidet P-40, and 0.3 mM DTT with protease inhibitor), proteins were eluted in sample buffer and resolved by SDS-PAGE and then autoradiographed and scanned by a PhosphoImager (Amersham Biosciences).
###end p 49
###begin title 50
Ubiquitylation assays.
###end title 50
###begin p 51
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020116-b047">47</xref>
###xml 339 340 339 340 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 506 509 503 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 515 518 512 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 611 612 607 608 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
For ubiquitylation assays, cell extracts with WT or mutant myc-tagged LANA expression were immunoprecipitated with anti-myc antibody and protein A/G Sepharose fast flow as described previously [47]. After three washes with binding buffer and two washes with a buffer containing 40 mM HEPES-NaOH (pH 7.9), 60 mM potassium acetate, 1 mM MgCl2, 0.5 mM EDTA, 10% glycerol, and 2 mM DTT, the beads were mixed with 500 ng of Uba1, 1.4 mug of Ubc5a, and 2.5 mug of GST-ubiquitin or His-ubiquitin with 2.5 mug GST-p53 (GST-VHL) in a 15-mul reaction containing 4 mM HEPES-NaOH (pH 7.9), 6 mM potassium acetate, 5 mM MgCl2, 1 mM DTT, and 1.5 mM ATP. Reaction mixtures were incubated for 1 h at 30 degreesC. Reaction products were fractionated by SDS-PAGE and analyzed by IB with anti-GST antibody.
###end p 51
###begin title 52
RT-PCR.
###end title 52
###begin p 53
###xml 46 49 46 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 53 56 53 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 412 413 411 412 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 721 725 717 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53,</italic>
###xml 786 789 782 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 846 852 842 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH,</italic>
RT-PCR was used to compare the mRNA levels of p53 or VHL in BCBL-1 cells with LANA knockdown or without. Total RNA was isolated by using TriZOL reagent (Invitrogen) following the manufacturer's protocol. RT-PCR was performed by using SuperScript II RT kit (Invitrogen) following the manufacturer's instructions. Briefly, RT-PCR was done in a total volume of 20 mul containing 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 200 muM concentration of each deoxynucleotide triphosphate, 2 muM concentration of each primer, 2 mul of randomly primed cDNA, and 0.5 unit of AmpliTaq (Applied Biosystems, Foster City, California, United States. Primers for desired gene (LANA, 5'-ATGTGACTTCGCCAACCGTAG-3' and 5'-TGCTTCTT CTGCAATCTCCG-3'; p53, 5'-CTCTCGGAACATCTCGAAGC-3' and 5'-GCG CACAGAGGAAGAGAATC-3'; VHL, 5'-GAAGAGTACGGCCCTGAA-3' and 5'-GGCAGTGTGATATTGGCA-3'; GAPDH, 5'-TGCACCACCAACTGCTTAG -3' and 5'-GATGCAGGGATGATGTTC-3') were included in some PCRs where indicated. PCR was done on an MJ Research Opticon II thermocycler (Waltham, Massachusetts, United States) by first heating the reaction at 94 degreesC for 5 min and then cycling the reaction 35 times with conditions set as 94 degreesC for 30 s, 50 degreesC for 30 s, and 72 degreesC for 30 s. Five microliters of the amplification products was analyzed by electrophoresis on 2% agarose gel and visualized after staining with ethidium bromide.
###end p 53
###begin title 54
Luciferase reporter assays.
###end title 54
###begin p 55
Luciferase reporter assays were performed after transient transfection of each construct as a reporter plasmid by following the manufacturer's protocol. Briefly, at 48 h posttransfection, 10 million transfected cells from each sample were harvested and subsequently washed once with PBS (Invitrogen), followed by lysis with 200 mul of reporter lysis buffer (Promega, Madison, Wisconsin, United States). A 40-mug total protein of the lysate was mixed with 100 mul of luciferase assay reagent. Luminescence was measured by the OpticompI Luminometer (MGM Instruments, Hamden, Connecticut, United States) for 10 s. Relative luciferase activity was expressed as fold activation relative to the reporter construct alone. The results shown represent experiments performed in triplicate.
###end p 55
###begin title 56
Supporting Information
###end title 56
###begin title 57
###xml 37 40 37 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 44 47 44 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
Aberrant Expression of LANA Conquers p53 or VHL as a Component of E3 Ubiquitin Complex for Degradation
###end title 57
###begin p 58
###xml 17 20 17 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 29 32 29 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 240 243 233 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 248 251 241 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 365 368 356 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 382 388 373 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(VHL),</italic>
###xml 476 479 464 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 483 486 471 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 542 545 530 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 549 552 537 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 644 653 628 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL, p53,</italic>
Tumor suppressor p53 (A) and VHL (B) competes with LANA. 786-O and Saos-2 cell lines were individually transfected with different doses (0, 1, 5, 10 mug) of LANA or cotransfected HIF-1alpha (5 mug) with different doses (0, 1, 5, 10 mug) of p53 (or VHL) in the presence or absence of LANA (2 mug) as indicated. Cell lysates (40 mug) underwent IB assays against myc (p53 or LANA), HA (VHL), and beta-actin as described previously. The data show that LANA can inhibit endogenous p53 or VHL in a dose-dependent manner, but higher-level exogenous p53 or VHL also can inhibit LANA expression and further suppress HIF-1alpha. Relative density (RD) of VHL, p53, and LANA protein was shown in lower panels.
###end p 58
###begin p 59
(92 KB PDF)
###end p 59
###begin p 60
Click here for additional data file.
###end p 60
###begin title 61
###xml 34 37 34 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 42 45 42 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
LANA Attenuates the Inhibition of p53 and VHL to Regulate the Transcriptional Activities of HIF-1alpha
###end title 61
###begin p 62
###xml 113 117 111 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL,</italic>
###xml 131 134 128 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 291 294 284 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 299 302 292 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 448 451 441 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 455 458 448 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
(A) BJAB, (B) 786-O, and (C) Saos-2 cells were cotransfected individually as indicated (10 mug of LANA, 5 mug of VHL, and 5 mug of p53). The multimeric hypoxia response element (HRE) promoter with luciferase reporter was used to detect the transcriptional activity of HIF-1alpha affected by VHL and p53. The transfected cell lysates underwent luciferase reporter assay as described previously. The data showed the LANA attenuates the inhibition of VHL or p53 to HIF-1alpha to increase transcription of HRE-containing promoter. The transcriptional activity of HIF-1alpha was expressed as the fold activation relative to activity with responding reporter construct alone (control). Means and standard deviations from three independent experiments are shown.
###end p 62
###begin p 63
(19 KB PDF)
###end p 63
###begin p 64
Click here for additional data file.
###end p 64
###begin title 65
###xml 70 73 70 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 78 81 78 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
Proposed Model for Viral Protein LANA Interacts with Cellular Protein VHL and p53
###end title 65
###begin p 66
###xml 90 91 90 91 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 139 142 139 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 147 150 147 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 290 293 290 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 303 306 303 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
During virus invasion, KSHV-encoded LANA is aberrantly expressed and possesses cellular EC5S ubiquitin complex to induce tumor suppressors VHL and p53 for degradation. In the other hand, the housekeeper genes encoded proteins in host cells together perform regular cellular mechanism, like VHL EC2S and p53 SCF ubiquitin pathway, to defense against infection via inhibiting viral protein expression.
###end p 66
###begin p 67
(14 KB PDF)
###end p 67
###begin p 68
Click here for additional data file.
###end p 68
###begin title 69
Accession Numbers
###end title 69
###begin p 70
###xml 221 224 221 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 238 241 238 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
The National Center for Biotechnology Information (NCBI) () accession numbers are KSHV (NC_003409), LANA (U52064), Elongin C (BC013809), Elongin B (BC065000), Cullin 2 (NM_003591), Cullin 5 (NM_003478), Rbx 1 (BC001466), VHL (NM_198156), p53 (NM_000546), and HIF-1alpha (U22431).
###end p 70
###begin p 71
We are grateful to Bala Chandran, Bill Kaelin, Craig B. Thompson, George Mosialos, Gregg L. Semenza, Joan W. Conaway, Jon Aster, Michael Lagunoff, Volker H. Haase, William G. Kaelin, Xiao-Fang Yu, and Yue Xiong for providing reagents. Special thanks go to members of the Robertson lab for suggestions and supports.
###end p 71
###begin title 72
Abbreviations
###end title 72
###begin p 73
amino acids
###end p 73
###begin p 74
Elongin B and C
###end p 74
###begin p 75
Cullin
###end p 75
###begin p 76
Elongin C-Cullin2/5-SOCS-box
###end p 76
###begin p 77
hemagglutinin
###end p 77
###begin p 78
hypoxia-inducible factor 1alpha
###end p 78
###begin p 79
###xml 12 13 12 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
glutathione S-transferase
###end p 79
###begin p 80
immunoblotting
###end p 80
###begin p 81
immunoprecipitation
###end p 81
###begin p 82
Kaposi's sarcoma
###end p 82
###begin p 83
Kaposi's sarcoma-associated herpesvirus
###end p 83
###begin p 84
latency-associated nuclear antigen
###end p 84
###begin p 85
primary effusion lymphoma
###end p 85
###begin p 86
Skp1-Cullin1-F-box
###end p 86
###begin p 87
suppressors of cytokine signaling
###end p 87
###begin p 88
ubiquitin
###end p 88
###begin p 89
von Hippel-Lindau gene
###end p 89
###begin p 90
wild-type
###end p 90
###begin title 91
References
###end title 91
###begin article-title 92
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma
###end article-title 92
###begin article-title 93
Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells
###end article-title 93
###begin article-title 94
###xml 184 202 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus
###end article-title 94
###begin article-title 95
###xml 0 19 <span type="species:ncbi:37296">Human herpesvirus 8</span>
Human herpesvirus 8 latent-state gene expression and apoptosis in Kaposi's sarcoma lesions
###end article-title 95
###begin article-title 96
###xml 109 114 <span type="species:ncbi:9606">human</span>
Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells
###end article-title 96
###begin article-title 97
DNA binding and modulation of gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus
###end article-title 97
###begin article-title 98
Modulation of cellular and viral gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus
###end article-title 98
###begin article-title 99
Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: A potential mechanism for virus-mediated control of latency
###end article-title 99
###begin article-title 100
Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mediates episome persistence through cis-acting terminal repeat (TR) sequence and specifically binds TR DNA
###end article-title 100
###begin article-title 101
Definition of sequence requirements for latency-associated nuclear antigen 1 binding to Kaposi's sarcoma-associated herpesvirus DNA
###end article-title 101
###begin article-title 102
###xml 79 84 <span type="species:ncbi:9606">human</span>
Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) binds ATF4/CREB2 and inhibits its transcriptional activation activity
###end article-title 102
###begin article-title 103
###xml 0 19 <span type="species:ncbi:37296">Human herpesvirus 8</span>
###xml 107 125 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells
###end article-title 103
###begin article-title 104
The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: Role of the KSHV latency-associated nuclear antigen and the AP1 response element
###end article-title 104
###begin article-title 105
###xml 20 39 <span type="species:ncbi:37296">human herpesvirus 8</span>
Carboxy terminus of human herpesvirus 8 latency-associated nuclear antigen mediates dimerization, transcriptional repression, and targeting to nuclear bodies
###end article-title 105
###begin article-title 106
Physical and functional interactions between STAT3 and Kaposi's sarcoma-associated herpesvirus-encoded LANA
###end article-title 106
###begin article-title 107
A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency
###end article-title 107
###begin article-title 108
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
p53 inhibition by the LANA protein of KSHV protects against cell death
###end article-title 108
###begin article-title 109
###xml 153 156 <span type="species:ncbi:10116">rat</span>
The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells
###end article-title 109
###begin article-title 110
###xml 137 140 137 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function
###end article-title 110
###begin article-title 111
Mechanisms underlying ubiquitination
###end article-title 111
###begin article-title 112
Ubiquitin ligases and the immune response
###end article-title 112
###begin article-title 113
The ubiquitin system
###end article-title 113
###begin article-title 114
###xml 95 98 95 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 30 50 <span type="species:ncbi:10566">human papillomavirus</span>
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
###end article-title 114
###begin article-title 115
###xml 59 64 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex
###end article-title 115
###begin article-title 116
A major step on the road to understanding a unique posttranslational modification and its role in a genetic disease
###end article-title 116
###begin article-title 117
A hitchhiker's guide to the cullin ubiquitin ligases: SCF and its kin
###end article-title 117
###begin article-title 118
Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade
###end article-title 118
###begin article-title 119
Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex
###end article-title 119
###begin article-title 120
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
###end article-title 120
###begin article-title 121
VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases
###end article-title 121
###begin article-title 122
Targeting of protein ubiquitination by BTB-Cullin 3-Roc1 ubiquitin ligases
###end article-title 122
###begin article-title 123
BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3
###end article-title 123
###begin article-title 124
Cullin-based ubiquitin ligases: Cul3-BTB complexes join the family
###end article-title 124
###begin article-title 125
The BTB protein MEL-26 is a substrate-specific adaptor of the CUL-3 ubiquitin-ligase
###end article-title 125
###begin article-title 126
Control of the SCF (Skp2-Cks1) ubiquitin ligase by the APC/C (Cdh1) ubiquitin ligase
###end article-title 126
###begin article-title 127
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase
###end article-title 127
###begin article-title 128
Kaposi's sarcoma-associated herpesvirus K3 utilizes the ubiquitin-proteasome system in routing class major histocompatibility complexes to late endocytic compartments
###end article-title 128
###begin article-title 129
A novel class of herpesvirus-encoded membrane-bound E3 ubiquitin ligases regulates endocytosis of proteins involved in immune recognition
###end article-title 129
###begin article-title 130
Ubiquitination on nonlysine residues by a viral E3 ubiquitin ligase
###end article-title 130
###begin article-title 131
###xml 9 14 <span type="species:ncbi:9606">human</span>
c-MIR, a human E3 ubiquitin ligase, is a functional homolog of herpesvirus proteins MIR1 and MIR2 and has similar activity
###end article-title 131
###begin article-title 132
Hypoxia-inducible factor (HIF-1)alpha: Its protein stability and biological functions
###end article-title 132
###begin article-title 133
###xml 10 15 <span type="species:ncbi:9606">human</span>
HIF-1 and human disease: One highly involved factor
###end article-title 133
###begin article-title 134
Hypoxia: A key regulatory factor in tumour growth
###end article-title 134
###begin article-title 135
###xml 36 39 36 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha
###end article-title 135
###begin article-title 136
Muf1, a novel Elongin BC-interacting leucine-rich repeat protein that can assemble with Cul5 and Rbx1 to reconstitute a ubiquitin ligase
###end article-title 136
###begin article-title 137
###xml 22 27 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines
###end article-title 137
###begin article-title 138
ASB2 is an Elongin BC-interacting protein that can assemble with Cullin 5 and Rbx1 to reconstitute an E3 ubiquitin ligase complex
###end article-title 138
###begin article-title 139
KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma
###end article-title 139
###begin article-title 140
###xml 24 43 <span type="species:ncbi:37296">human herpesvirus 8</span>
The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): Distribution of infection in KS risk groups and evidence for sexual transmission
###end article-title 140
###begin article-title 141
Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen
###end article-title 141
###begin article-title 142
The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells
###end article-title 142
###begin article-title 143
The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families
###end article-title 143
###begin article-title 144
Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products
###end article-title 144
###begin article-title 145
Targeting HIF-1 for cancer therapy
###end article-title 145
###begin article-title 146
###xml 101 106 <span type="species:ncbi:9606">human</span>
The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages
###end article-title 146
###begin article-title 147
###xml 60 65 <span type="species:ncbi:9606">human</span>
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases
###end article-title 147
###begin article-title 148
Development of Kaposi's sarcoma at the site of a biopsy
###end article-title 148
###begin article-title 149
Mammalian mediator subunit mMED8 is an Elongin BC-interacting protein that can assemble with Cul2 and Rbx1 to reconstitute a ubiquitin ligase
###end article-title 149
###begin article-title 150
###xml 15 18 15 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex
###end article-title 150
###begin article-title 151
Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus
###end article-title 151
###begin article-title 152
###xml 64 83 <span type="species:ncbi:37296">human herpesvirus 8</span>
Identification of a major latent nuclear antigen, LNA-1, in the human herpesvirus 8 genome
###end article-title 152
###begin article-title 153
###xml 100 119 <span type="species:ncbi:37296">human herpesvirus 8</span>
The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen
###end article-title 153
###begin article-title 154
###xml 108 113 <span type="species:ncbi:9606">human</span>
Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus up-regulates transcription of human telomerase reverse transcriptase promoter through interaction with transcription factor Sp1
###end article-title 154
###begin article-title 155
###xml 9 28 <span type="species:ncbi:10381">herpesvirus saimiri</span>
ORF73 of herpesvirus saimiri, a viral homolog of Kaposi's sarcoma-associated herpesvirus, modulates the two cellular tumor suppressor proteins p53 and pRb
###end article-title 155
###begin article-title 156
Establishment and maintenance of Kaposi's sarcoma-associated herpesvirus latency in B cells
###end article-title 156
###begin title 157
Figures and Tables
###end title 157
###begin title 158
LANA Associates with the Elongin BC Complex
###end title 158
###begin p 159
###xml 291 293 291 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
(A) The amino-terminal domain of LANA directly interacts with Elongin C but not Elongin B in vitro. The cDNA encoding N (1-340 aa), C (762-1162 aa), or NC (1-327̂929-1162 aa) truncation of LANA with myc tagged were expressed in a coupled transcription/translation system in the presence of [35S]methionine. Aliquots (20 mul) of the translation products were pulled down by GST, GST-Elongin C, or GST-Elongin B, respectively. The pulldown complex as well as a 1-mul aliquot of the transcription/translation reaction (Input) were fractionated by SDS-PAGE, and detected by a PhosphorImager. The proteins of GST and GST fused with Elongin B or Elongin C were shown by Coomassie staining in the right panel.
###end p 159
###begin p 160
###xml 80 82 80 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
(B) Elongin C is critical for LANA binding to Elongin B. In vitro produced and [35S]-labeled proteins LANA N (1-340 aa), Elongin C, and Elongin B were incubated with anti-myc antibodies. The interacting complexes were resolved by SDS-PAGE and examined by a PhosphorImager.
###end p 160
###begin p 161
(C) LANA associates with Elongin BC complex in KSHV-infected cells. Cell lysates of BCBL-1, DG-75, BJAB, or BJAB with KSHV infection (K-BJAB) were subjected to IP against LANA or Elongin C (Elo. C) followed by IB against LANA, Elongin C, and Elongin B (Elo. B).
###end p 161
###begin title 162
The LANA-Elongin BC Complex Assemble with the Cul5/Rbx1 Module
###end title 162
###begin p 163
(A) LANA protein associates with the Cul5/Rbx1 module but not Cul2/Rbx1 module, and (B) Elongin BC complex increases interaction of LANA with the Cul5/Roc1 module. Saos-2 cells were transfected with expression vector encoding the indicated proteins in the figure. The lysates underwent IP using anti-myc antibodies. Crude extracts (left panels) and immune complexes (right panels) were separated by SDS-PAGE and IB with the indicated antibodies.
###end p 163
###begin title 164
LANA Associates with the Elongin BC Complex and Cul5 through the SOCS-Box-Like Motif
###end title 164
###begin p 165
###xml 495 514 <span type="species:ncbi:10381">herpesvirus saimiri</span>
###xml 516 519 <span type="species:ncbi:11029?0.43884892086330934|species:ncbi:154334?0.05755395683453238">RRV</span>
###xml 521 534 <span type="species:ncbi:9544">rhesus monkey</span>
(A) KSHV LANA contains a putative SOCS-box motif which includes a consensus of BC-box and Cul-box motifs. Upper panels show hydrophobic sequence alignment of the BC-box and Cul-box motifs from viral LANA and cellular SOCS-box-containing proteins that bind Elongin BC and Cullin proteins individually. Conserved residues with similarity are shaded in the upper panel. Lower panels show ORF73 proteins from other gammaherpesvirus contain an SOCS-box-like motif which is similar to KSHV LANA. HVS, herpesvirus saimiri; RRV, rhesus monkey rhadinovirus. The site mutations of LANA in leucine (L) and/or cystine (C) are indicated with underlining.
###end p 165
###begin p 166
(B) LANA associates with the Elongin BC complex through the BC-box motif. Saos-2 cells were transfected with expression vector encoding the indicated proteins. The WT LANA and its mutant with BC-box (DeltaBC) deletion and point mutation (LPCF, L213G or C217G) within BC box were compared. Since LANA lost its normally top bands (approximately 230 kDa) in the L213G mutant, another two lower bands of LANA (between 190 kDa and 230 kDa) were specifically present. The lysates underwent IP and IB assays as described previously. RD, relative density.
###end p 166
###begin p 167
(C) LANA associates with Cullin 5 through the Cul-box motif. Saos-2 cells were transfected with expression vector encoding the indicated proteins. The WT LANA with Cul-box (DeltaCul) or SOCS-box (DeltaSCOS) deletion was compared. The lysates underwent IP and IB assays as described previously. Crude extracts (left panels) and immune complexes (right panels) are shown.
###end p 167
###begin p 168
###xml 253 261 253 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g003">Figure 3</xref>
###xml 312 320 312 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g003">Figure 3</xref>
(D) LANA assembles with Elongin BC complex and Cul5/Rbx1 module to reconstitute a multiprotein complex with E3 ubiquitin ligase activity. Left panel shows the LANA-Elongin BC-Cul5-Rbx1 complex had ubiquitin ligase activity. The cell lysates of WT LANA (Figure 3C, lane 4) or SOCS-box-like motif deletion mutant (Figure 3C, lane 3) as control was subjected to anti-myc immunoaffinity purification. The purified LANA immune complex (IC) was incubated with various combinations of Uba1 (E1), Ubc5a (E2), and GST-ubiquitin (GST-Ub) in the absence or presence of ATP, to assess its ability to stimulate ubiquitylation in vitro. The proteins were separated by SDS-PAGE and IB using anti-GST antibodies. Right panel shows SOCS-box-like motif deletion reduced the capacity of LANA to induce polyubiquitylation. Saos-2 cells were transfected with WT LANA or its SOCS mutant. After 24-h transfection, cells were treated with MG132 (0.5 muM) for 2 h. Lysates were subjected to IB against Ub or myc antibodies.
###end p 168
###begin title 169
Binding to the Elongin BC Complex Stabilizes LANA
###end title 169
###begin p 170
(A) The stabilities of WT LANA and its SOCS motif mutant. Five million Saos-2 cells were transfected with 5 mug of LANA-WT (left panel) or LANA-DeltaSOCS (right panel) expression vector in the presence of 5 mug of Elongin B and 5 mug of Elongin C expression vectors, as indicated. Twenty-four hours after transfection, cells were treated with 100 mug/ml cyclohexamide (CHX) for different times (0, 5, 10, and 24 h). Aliquots (40 mug) of each whole-cell extract underwent IB with the indicated antibodies.
###end p 170
###begin p 171
(B) The relative levels of WT LANA and its SOCS mutant coexpression with Elongin BC complex. Protein density was quantitated by densitometry of immunoblots using Odyssey Image v1.2 from three separate experiments.
###end p 171
###begin title 172
###xml 22 25 22 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 30 33 30 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
The Tumor Suppressors p53 and VHL Are Inhibited in the KSHV Latently Infected and LANA-Expressing Cells
###end title 172
###begin p 173
###xml 140 143 140 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 145 149 145 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL,</italic>
###xml 243 246 240 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 290 293 287 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 344 347 341 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 388 391 382 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 396 399 390 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
(A) IB analysis of KSHV-positive cell lines (BC-3, BCBL-1, JSC-1, and BC-1) and KSHV-negative cell lines (BJAB, DG-75, and Louckes) against p53, VHL, and beta-actin. Ten million of each cell line were lysed and coimmunoprecipitated using anti-VHL antibodies followed by detection with anti-VHL. Cell lysate (5%) was used in IB assays with anti-p53 and anti-beta-actin. The data show that p53 and VHL in KSHV-positive cells are more strongly inhibited than in KSHV-negative cells.
###end p 173
###begin p 174
###xml 188 191 188 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 235 238 235 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 293 297 293 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53,</italic>
(B) The levels of p53 and VHL protein in B-lymphoma cells with KSHV latent infection. Ten million BJAB- or KSHV-infected BJAB (k-BJAB) cells were lysed and coimmunoprecipitated using anti-VHL antibodies followed by detection with anti-VHL. Cell lysate (5%) was used in IB assays against LANA, p53, and beta-actin. The data showed that the tumor suppressor proteins p53 and VHL were inhibited during KSHV infection.
###end p 174
###begin p 175
###xml 4 7 4 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 12 15 12 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 156 160 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53,</italic>
###xml 165 168 165 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 247 250 247 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 255 258 255 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
(C) p53 and VHL are inhibited in the LANA stable expressing cells. Ten million 293/LANA or 293/Vector stable cell lysates were analyzed by IB against LANA, p53, and VHL as described previously. The data showed that LANA decreases tumor suppressor p53 and VHL levels.
###end p 175
###begin p 176
###xml 4 7 4 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 12 15 12 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 211 220 211 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53, VHL,</italic>
(D) p53 and VHL turnover in the LANA knockdown BCBL-1 cells. Cell lysates from stable BCBL-1 cells with LANA or control firefly luciferase knockdown (RNAi) were subjected to IB assays (left panel) against LANA, p53, VHL, and beta-actin, or total RNA underwent RT-PCR analysis (right panel). RD, relative density.
###end p 176
###begin title 177
###xml 57 60 57 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 65 68 65 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
Distinct Domains of LANA Interact with Tumor Suppressors p53 and VHL
###end title 177
###begin p 178
###xml 46 49 46 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 87 90 87 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 208 211 208 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 294 296 294 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
(A) The amino-terminal domain of LANA binding VHL and carboxyl-terminal domain binding p53 in vitro. The cDNA encoding N (1-340 aa), C (762-1162 aa), and NC (1-327̂929-1162 aa) LANA with myc tag, HA-VHL, and p53 were translated in a coupled transcription/translation system in the presence of [35S]methionine. Fifteen-microliter aliquots of the translation products were immunoprecipitated with anti-myc antibodies. Immunoprecipitated proteins (IP) and a 1-mul aliquot of the transcription/translation reaction (Input) were fractionated by SDS-PAGE and detected by autoradiography. RD, relative density.
###end p 178
###begin p 179
###xml 28 31 28 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 36 39 36 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
(B) LANA is associated with p53 and VHL in cells. Saos-2 cells were cotransfected with expression vector encoding the indicated proteins. The lysates underwent IP using anti-myc antibodies. Crude extracts (left panels) and immune complexes (right panels) were separated by SDS-PAGE and IB with antibodies indicated. Asterisk indicates IgG heavy chain.
###end p 179
###begin title 180
###xml 54 57 54 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 62 65 62 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
LANA Promotes Polyubiquitylation of Tumor Suppressors p53 and VHL
###end title 180
###begin p 181
###xml 17 20 17 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 25 28 25 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 181 184 177 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 395 398 390 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 403 406 398 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 457 460 449 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 465 468 457 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
(A) LANA induces p53 and VHL polyubiquitylation. Saos-2 (left panel) or 786-O (right panel) cells were cotransfected with different combinations of myc-LANA (WT and DeltaSOCS), myc-p53 (or HA-VHL), and HA-Ub as indicated. At 48 h posttransfection, transfected cells were harvested, lysed, and protein normalized. Total protein (40 mug) was subjected to resolve and IB assays against myc (LANA), p53 (or VHL), and beta-actin. The data showed LANA can induce p53 and VHL ubiquitylation in vivo.
###end p 181
###begin p 182
###xml 50 53 50 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 58 61 58 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 120 128 120 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g003">Figure 3</xref>
###xml 179 187 179 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020116-g003">Figure 3</xref>
(B) The LANA-Elongin BC-Cul5-Rbx1 complex induces p53 and VHL polyubiquitylation in vitro. The cell lysates of WT LANA (Figure 3C, lane 4) or SOCS-box-like motif deletion mutant (Figure 3C, lane 3) as control was subjected to anti-myc immunoaffinity purification. The purified LANA immune complex (IC) was incubated with various combinations of Uba1 (E1), Ubc5a (E2), His-Ub, or GST-VHL (or GST-p53) in the presence of ATP in vitro. The proteins were separated by SDS-PAGE and IB against GST antibody. Left panel, GST-p53; right panel, GST-VHL.
###end p 182
###begin title 183
###xml 34 35 34 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
A Model for KSHV LANA Assembles EC5S Ubiquitin Complex to Target Downstream Substrates for Degradation
###end title 183
###begin p 184
###xml 241 244 237 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 249 252 245 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 259 260 255 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
LANA is predicted to form a complex with Cul5/Rbx1 that interacts with Elongin BC but not LANA DeltaSOCS (Cul box and BC box) mutant. LANA acts as adapter to link substrates which bind at its amino (1) or carboxyl (2) -terminal domain (like VHL and p53) to EC5S ubiquitin complex and induces the pathway of ubiquitin E1 activation, E2 conjugation, and substrate polyubiquitylation as well as 26S proteasome-mediated degradation.
###end p 184
###begin p 185
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 185
###begin p 186
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
###xml 186 189 <span type="species:ncbi:227859?0.03787878787878788">SCV</span>
###xml 342 345 <span type="species:ncbi:227859?0.03787878787878788">SCV</span>
Author contributions. ESR supervised the overall design and execution of all experiments from initiation to submission of the manuscript. QLC designed and executed the experiments. JSK, SCV, and PZ assisted in performing some of the experiments and analysis of the generated data. ESR and QLC reviewed the analysis of all the data. QLC, JSK, SCV, and PZ contributed reagents/materials/analysis tools. ESR and QLC wrote and submitted the manuscript.
###end p 186
###begin p 187
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. This work was supported by US Public Health Service grants NCI CA072510 and CA091792, NIDCR DE014136, NIAID AI067037, and DE17338 (to ESR). ESR is a scholar of the Leukemia and Lymphoma Society of America.
###end p 187

